nsaid-safety

# NSAID Safety ## Overview Evidence-based NSAID selection, dosing by species, contraindication recognition, and safety monitoring protocols. Includes COX-1 vs. COX-2 selectivity comparison, renal/GI risk stratification, and drug interaction management. ## When to Use - User prescribes NSAID or assesses drug safety for concurrent NSAID use - User needs NSAID selection, dosing verification, or renal/GI monitoring plan - Keywords: NSAID, meloxicam, carprofen, deracoxib, firocoxib, robenacoxib, GI ulcer, renal, COX, anti-inflammatory, contraindication, drug interaction ## NSAID Comparison Table | Drug | Species | Dose | Route | Frequency | COX Selectivity | Comments | |---|---|---|---|---|---|---| | **Meloxicam** | Dog | 0.1-0.2 mg/kg | PO/IV/SC | Daily | COX-2 preferential | Longer half-life (12-18h); IV/SC option; first-line many practices | | | Cat | 0.05 mg/kg/day (chronic, lowest effective) | PO/SC | See warning | COX-2 preferential | ⚠️ **FDA BLACK-BOX WARNING**: repeated dosing causes fatal acute renal failure in cats. US label = **single one-time** 0.3 mg/kg SC only. Chronic use (EU label / off-label US) = **0.05 mg/kg once daily** max with mandatory renal monitoring. Avoid the 0.3–0.5 mg/kg q48h regimen — not an established safe protocol | | | Rabbit | 0.6-1 mg/kg | PO/SC | BID | COX-2 preferential | Limited data; anecdotal use; monitor renal/GI closely | | **Carprofen** | Dog | 4.4 mg/kg/day (2.2 mg/kg BID **or** 4.4 mg/kg SID) | PO/IV | BID or SID | COX-2 preferential (mild) | **Do not exceed 4.4 mg/kg/day; not dosed TID.** Shorter half-life (~8h); idiosyncratic hepatotoxicity reported (classically Labradors) | | | Cat | 1-2 mg/kg | PO/IV | BID | COX-2 preferential (mild) | Limited feline data; less commonly used in cats; GI ulceration risk higher than meloxicam | | **Deracoxib** | Dog | 1-2 mg/kg | PO | Daily | COX-2 selective | Food-dependent absorption (give with food); 5-7 day max acute, 30 days chronic (FDA restriction) | | **Firocoxib** | Dog | 5 mg/kg | PO | Daily | COX-2 highly selective | Canine (Previcox) dose. ⚠️ The **equine** dose is far lower (0.1 mg/kg) — never cross-apply; less GI ulceration than carprofen; expensive | | | Horse | **0.1 mg/kg PO** (Equioxx); ~0.09 mg/kg IV | PO/IV | Daily | COX-2 highly selective | Equine label is **0.1 mg/kg** — 5 mg/kg would be a ~50× overdose (oral/GI ulceration, renal papillary necrosis); longer plasma half-life | | **Robenacoxib** | Dog/Cat | 1-2 mg/kg | SC/IV | Daily × 4-10 days | COX-2 selective | Short-term use primarily; less renal effects at short durations; expensive; limited US availability | ## COX-1 vs. COX-2 Selectivity **COX-1 Functions**: Gastric mucosal protection (prostaglandins), platelet aggregation, renal hemodynamics, tissue homeostasis - **Inhibition consequence**: GI ulceration, platelet dysfunction, renal perfusion reduction **COX-2 Functions**: Inflammation, fever, pain; also renal and gastric roles in chronic settings - **Selectivity advantage**: Lower GI ulceration risk; some renal protective effects at lower doses **Clinical Implication**: COX-2 selective agents (meloxicam, firocoxib, deracoxib, robenacoxib) safer GI profiles than less-selective agents (carprofen) in short-term use; long-term use blunts selectivity advantage ## GI Ulceration Risk Factors **Intrinsic Risk** (patient factors): - Age (geriatric >7 years; puppies/kittens immature mucosa) - Concurrent disease (inflammatory bowel disease, gastric ulcer history, neoplasia) - Hepatic/renal disease (reduced clearance, decreased perfusion) - Hypoproteinemia (<5.0 g/dL; reduced gastric mucosa protection) - Dehydration (reduced gastric blood flow) - NSAIDs increase risk 4-6× in dogs; cats lower baseline risk but elevation if predisposed **Extrinsic Risk** (drug factors): - High NSAID dose - Prolonged duration (risk increases after 2-4 weeks) - Concurrent corticosteroid use (synergistic ulceration risk; **contraindicated**) - Concurrent anticoagulant (inhibited platelet aggregation) - Multiple NSAIDs (avoid combining even "safer" pairs) **Gastroduodenal Complications**: - **Grade 1**: Gastric mucosal erythema, no erosion; asymptomatic - **Grade 2**: Erosions <3 mm; vomiting possible - **Grade 3-4**: Ulcers >3 mm, perforation risk; hematemesis, melena, severe pain ## Renal Monitoring Protocol **Baseline Assessment** (before NSAID initiation): - Serum creatinine, BUN, urine specific gravity (USG) - Contraindicate NSAID if: Cr >1.8 mg/dL (dogs), >1.6 mg/dL (cats); pre-existing renal disease; dehydration present **During Therapy**: - Recheck BUN/creatinine at 7-10 days if new NSAID (acute phase kidney injury risk peaks early) - Repeat at 2-4 weeks if continuing >2 weeks duration - For chronic NSAIDs (months+): Check q3-6 months **Renal NSAID Mechanism**: - Decrease renal perfusion (COX-2 inhibition reduces renal vasodilation) - Acute kidney injury risk in hypovolemic/dehydrated states - Chronic risk: Progressive glomerulosclerosis with prolonged high-dose use **Discontinuation Indications**: - Creatinine increase >0.5 mg/dL from baseline - BUN >40 mg/dL without other explanation - Evidence of acute kidney injury (azotemia + clinical signs) - Oliguria/polyuria development ## Species-Specific Dosing and Considerations ### Dogs - **Standard dose**: Meloxicam 0.1-0.2 mg/kg daily; carprofen 4.4 mg/kg/day (2.2 mg/kg BID or 4.4 mg/kg SID — do not exceed) - **Geriatric/renal disease**: Reduce to minimum effective dose; meloxicam 0.1 mg/kg daily preferred (less renal impact) - **Post-operative**: Start pre-operatively (pre-emptive analgesia); continue 5-7 days minimum - **Chronic orthopedic disease**: Long-term meloxicam acceptable with monitoring; consider adjuvant agents (gabapentin, joint supplements) to minimize NSAID requirements ### Cats - **Meloxicam — FDA black-box warning**: Repeated dosing in cats is associated with acute renal failure and death. In the US, meloxicam is approved only as a **single, one-time** SC dose (0.3 mg/kg) for surgical pain; any repeated dosing is off-label and carries the black-box warning. - **Chronic use (where justified, e.g. EU label for musculoskeletal pain)**: dose at the **lowest effective dose, ~0.05 mg/kg once daily**, with **mandatory** renal monitoring (USG, BUN, creatinine, SDMA). - **Avoid**: the 0.3–0.5 mg/kg q48h regimen — it is not an established safe protocol and is a documented mechanism of feline NSAID toxicity. - **GI risk**: Cats more sensitive to severe GI ulceration than dogs despite lower overall baseline - **Renal monitoring**: Mandatory (USG, BUN, creatinine baseline and q2-4 weeks) - **Chronic use**: Short-term (acute pain, <2 weeks) preferred; long-term requires strong indication and close monitoring ### Rabbits/Small Mammals - **Meloxicam**: 0.6-1 mg/kg PO/SC BID common dosing (limited species-specific data) - **GI stasis risk**: Meloxicam may reduce appetite/motility; ensure adequate hydration and hay intake - **Carprofen**: Anecdotal use; minimal data; generally avoided - **Monitoring**: Renal monitoring less standardized; assess appetite, fecal output, hydration ### Horses - **Firocoxib**: **0.1 mg/kg** daily PO (Equioxx, approved equine label); superior to phenylbutazone (PBZ, older standard) in some pain models. (Note: the canine Previcox dose is 5 mg/kg — do not confuse the two; 5 mg/kg in a horse is a ~50× overdose.) - **Phenylbutazone**: Traditional (4.4 mg/kg daily max); longer-term GI ulceration risk; now second-line - **Monitoring**: Renal dysfunction less common in horses; GI ulceration still risk - **Maximum duration**: 30 days typically recommended (extended use controversial) ## Corticosteroid + NSAID Interaction **Mechanism**: Corticosteroids inhibit phospholipase A2 (blocks arachidonic acid release); NSAIDs inhibit COX; combined blockade → synergistic GI ulceration **Contraindication**: Absolute: Do NOT combine systemic corticosteroid + NSAID concurrently - **Washout period**: Discontinue corticosteroid ≥1 week before initiating NSAID OR discontinue NSAID ≥1 week before corticosteroid **Exception**: Topical corticosteroids (ophthalmic, dermal) + systemic NSAID generally safe (minimal systemic absorption) **Alternative**: Use NSAID + adjuvant analgesic (gabapentin, tramadol) instead of corticosteroid if possible ## Drug Interactions and Contraindications **NSAIDs + Anticoagulants** (warfarin, apixaban): Increased bleeding risk; avoid if possible; if necessary, use lowest NSAID dose, monitor INR closely **NSAIDs + ACE Inhibitors** (enalapril, lisinopril): Combined renal perfusion reduction; acceptable in euvolemic patients; contraindicated if dehydrated **NSAIDs + Diuretics**: Reduced renal perfusion; monitor renal function closely; ensure adequate hydration **NSAIDs + Methotrexate**: Reduced MTX clearance; potential toxicity; monitor closely **Absolute Contraindications**: - Acute/chronic kidney disease (Cr >1.8 dogs, >1.6 cats without specialist guidance) - Severe hepatic disease - Active GI ulceration (confirmed or high suspicion) - Platelet dysfunction disorders - Concurrent corticosteroid (system non-topical) - Hypersensitivity/allergy history ## GI Protection Strategies **H2 Blockers** (famotidine 0.5-1 mg/kg q12h): - Reduces gastric acid; modest ulceration prevention - Minimal evidence for routine prophylaxis in short-term NSAID use - Consider if: Geriatric, pre-existing GI disease, high-risk NSAID choice **Proton Pump Inhibitors** (omeprazole 0.5-1 mg/kg q24h): - Superior acid suppression to H2 blockers - Limited evidence for routine prophylaxis short-term - Consider if: High-risk patient, previous NSAID intolerance, chronic NSAID use **Misoprostol** (2-5 mcg/kg q6-8h): Prostaglandin analog; promotes gastric mucosa protection - Reduced diarrhea (side effect) in cats; avoid if GI dysmotility risk - Limited practical use due to dosing frequency **Evidence**: Routine GI protection not recommended for short-term (<2 weeks) NSAID use in low-risk patients; consider for high-risk or chronic use ## Monitoring and Patient Selection Workflow 1. **Assess renal function baseline**: Serum creatinine, BUN, USG; exclude if abnormal 2. **Assess GI risk**: History of ulceration, concurrent medications, age, dehydration status 3. **Select appropriate NSAID**: COX-2 selective (meloxicam, firocoxib) preferred over less-selective agents; meloxicam for cats with renal monitoring 4. **Verify no corticosteroid within 1 week**: Washout period essential 5. **Establish monitoring plan**: Recheck creatinine/BUN at 7-10 days if new prescription; q2-4 weeks if chronic; assess appetite/vomiting at each visit 6. **Educate owner**: Signs of GI ulceration (vomiting, melena, anorexia); signs of renal disease (polyuria, polydipsia, lethargy); importance of monitoring ## Limitations - **Baseline renal assessment**: Many animals have subclinical renal disease (eGFR reduced despite normal creatinine); urine protein assessment (UP:C) not routine in screening - **NSAID selectivity**: Clinical significance of COX-1 vs. COX-2 selectivity debated; all NSAIDs carry GI/renal risk at higher doses or longer duration - **Feline meloxicam dosing**: Significant controversy; "safe" dose remains undefined; individual variation large - **GI protection efficacy**: Limited high-quality evidence for routine prophylaxis; many protection strategies add cost without proven benefit in short-term use - **Chronic NSAID use**: Long-term safety data limited; adjuvant agents (gabapentin, joint supplements) may reduce NSAID requirements but evidence variable - **Referral**: Complex polypharmacy, unexplained renal elevation during NSAID therapy, or refractory pain → internist/pain specialist consideration